Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other... Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers.
- Mechanism
- Curator reviewed
HspE7 works by efficiently delivering the E7 antigen to dendritic cells, which have a natural affinity for Hsp. Dendritic cells are known to be the most potent cells in the body for triggering immune responses. Coupling E7 to Hsp takes advantage of the Hsp receptors that dendritic cells express on their surface to introduce E7, as part of a larger fusion protein, into the dendritic cells.
- Primary indication
- Investigated for use/treatment in anal dysplasia, cervical dysplasia/cancer, genital warts, HIV infection, infectious and parasitic disease (unspecified), pediatric indications, warts, and viral infection.Curator reviewed
- Also known as
- HspE7 · Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7
- Code names
- SGN-00101
Resolves to
What you can answer from here — as of October 01, 2026
Which drugs share a target with Verpasep caltespen, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account